← Eichor
Study identifier: NCT04944030 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clinico-biological Data Collection Study of Metastatic Lung Cancer

Condition: Lung Cancer  ·  Sponsor: Institut Cancerologie de l'Ouest

PhaseNA
Planned participants200
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

RATIONALE : Currently, the mechanisms associated with the response or resistance to treatment are poorly understood and are multifactorial. These mechanisms involve clinical and biological factors associated with the host and the tumor and possibly the patient's psycho-social environment. PURPOSE : This trial will assess the use of a prospective database dedicated to patients with breast cancers that contains clinical data as well as epidemiological, psychological, emotional, social, imaging, biological and biopathological data. These data will allow a creation of new modelling algorithms in order to predict response and resistance to treatment.

This description comes directly from the study's public registry record.

Talk to the study team

JUDITH RAIMBOURG, MD,PHD  ·  0240679900  ·  judith.raimbourg@ico.unicancer.fr

MARINE TIGREAT  ·  0240679878  ·  marine.tigreat@ico.unicancer.fr

Always discuss trial participation with your own doctor first.

Locations (2)

Institut de Cancerologie de L'OuestAngers, FranceRecruiting
Institut de Cancerologie de L'OuestSaint-Herblain, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04944030